ChiCTR2600119409 版本V1.0 版本创建时间2026/02/26 16:09:53 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600119409 

最近更新日期:

Date of Last Refreshed on:

2026-02-26 16:09:35 

注册时间:

Date of Registration:

2026-02-26 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

术中FiO?调控联合肺复张策略对头颈外科手术患者肺泡维持效果的影响

Public title:

Effect of Intraoperative FiO? Regulation Combined with Lung Recruitment Maneuver on Alveolar Maintenance Efficacy in Patients Undergoing Head and Neck Surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

术中FiO?调控联合肺复张策略对头颈外科手术患者肺泡维持效果的影响

Scientific title:

Effect of Intraoperative FiO? Regulation Combined with Lung Recruitment Maneuver on Alveolar Maintenance Efficacy in Patients Undergoing Head and Neck Surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

韩雨 

研究负责人:

高巨 

Applicant:

Yu Han 

Study leader:

Ju Gao 

申请注册联系人电话:

Applicant telephone:

+86 198 5532 1106

研究负责人电话:

Study leader's
telephone:

+86 180 5106 3988

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1375570398@qq.com

研究负责人电子邮件:

Study leader's E-mail:

doctor2227@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省扬州市南通西路98号

研究负责人通讯地址:

江苏省扬州市南通西路98号

Applicant address:

98 Nantong Western Road, Yangzhou 225001, Jiangsu, China.

Study leader's address:

98 Nantong Western Road, Yangzhou 225001, Jiangsu, China.

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

江苏省苏北人民医院

Applicant's institution:

Subei People's Hospital of Jiangsu province

研究负责人所在单位:

江苏省苏北人民医院

Affiliation of the Leader:

Subei People's Hospital of Jiangsu province

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025k302

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

江苏省苏北人民医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Subei People's Hospital of Jiangsu Province

伦理委员会批准日期:

Date of approved by ethic committee:

2025-09-22 00:00:00

伦理委员会联系人:

高巨

Contact Name of the ethic committee:

Ju Gao

伦理委员会联系地址:

江苏省扬州市南通西路98号 邮编225001

Contact Address of the ethic committee:

98 Nantong Western Road, Yangzhou 225001, Jiangsu, China.

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 180 5106 3988

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

江苏省苏北人民医院

Primary sponsor:

Subei People's Hospital of Jiangsu

研究实施负责(组长)单位地址:

江苏省扬州市南通西路98号

Primary sponsor's address:

98 Nantong Western Road, Yangzhou 225001, Jiangsu, China.

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

扬州

Country:

China

Province:

Jiangsu

City:

Yangzhou

单位(医院):

江苏省苏北人民医院

具体地址:

江苏省扬州市南通西路98号

Institution
hospital:

Subei People's Hospital of Jiangsu

Address:

98 Nantong Western Road, Yangzhou 225001, Jiangsu, China.

经费或物资来源:

Source(s) of funding:

No

研究疾病:

肺不张  

Target disease:

Atelectasis

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

该研究为单中心、前瞻性、随机对照研究,主要目的是探讨术中 FiO?调控联合肺复张策略对头颈部手术患者肺复张后肺顺应性改善持续时间的影响;次要目的是分析不同吸入氧浓度下,患者术毕肺不张程度、PACU 期间低氧血症发生率及氧疗持续时间,还有术后 3 天内肺部并发症发生率,以明确使患者受益的最佳吸入氧浓度。  

Objectives of Study:

This is a single-center, prospective, randomized controlled study. Its primary objective is to explore the impact of intraoperative FiO? regulation combined with lung recruitment strategy on the duration of improved lung compliance after lung recruitment in patients undergoing head and neck surgery. The secondary objectives are to analyze, under different inspired oxygen concentrations, the degree of atelectasis at the end of surgery, the incidence of hypoxemia and the duration of oxygen therapy during the PACU period, as well as the incidence of pulmonary complications within 3 days after surgery, so as to identify the optimal inspired oxygen concentration that benefits patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.ASA 分级 Ⅰ~Ⅱ 级者; 2.签署知情同意书,自愿参加本项研究; 3.择期行全身麻醉头颈部手术患者; 4.性别不限,年龄 18-64 岁,体重指数(BMI)18-25 kg/m2; 5.预计手术时间≥1.5 小时,术中出血≤200 毫升者。

Inclusion criteria

1. Patients with ASA Physical Status Classification Ⅰ-Ⅱ; 2. Voluntarily participate in this study and sign the informed consent form; 3. Patients undergoing elective head and neck surgery under general anesthesia; 4. No restriction on gender; aged 18-64 years; Body Mass Index (BMI) 18-25 kg/m2; 5. Patients with an expected operation duration of >=1.5 hours and estimated intraoperative blood loss of <=200 ml.

排除标准:

1.既往曾行胸科手术者; 2.胸片或 CT 提示存在气胸或肺大泡者; 3.患有肺部疾病者,包括慢性支气管炎、哮喘、中重度阻塞性通气功能障碍; 4.术前呼吸空气时脉搏血氧饱和度(pulse oxygen saturation, SpO2)<90%,或吸氧状态下 SpO2<95% 者; 5.存在肺复张禁忌症者,包括高颅内压、低血容量休克、右心衰竭; 6.患有严重心脏疾病者,包括纽约心脏协会(New York Heart Association, NYHA)心功能分级 Ⅲ 级或 Ⅳ 级、急性冠状动脉综合征、持续性室性快速性心律失常; 7.正在参与其他干预性研究,或拒绝入组者。

Exclusion criteria:

1. Patients with a history of thoracic surgery; 2. Patients with chest X-ray or CT indicating pneumothorax or pulmonary bullae; 3. Patients with pulmonary diseases, including chronic bronchitis, asthma, and moderate to severe obstructive ventilatory dysfunction; 4. Patients with preoperative pulse oxygen saturation (SpO2) < 90% while breathing ambient air, or SpO2 < 95% with oxygen supplementation; 5. Patients with contraindications for lung recruitment, including high intracranial pressure, hypovolemic shock, and right heart failure; 6. Patients with severe heart diseases, including New York Heart Association (NYHA) Class Ⅲ or Ⅳ heart failure, acute coronary syndrome, and sustained ventricular tachyarrhythmia; 7. Patients currently participating in other interventional studies, or those who refuse to be enrolled.

研究实施时间:

Study execute time:

From 2025-11-20 00:00:00 To 2026-02-03 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-01-01 00:00:00 To 2026-01-30 00:00:00

干预措施:

Interventions:

组别:

A组

样本量:

14

Group:

Group A

Sample size:

干预措施:

麻醉诱导后,待药物完全起效后行气管插管FiO2设置为40%,手术开始后调整为各组吸入氧浓度,5min后调整FiO2为21%,行肺复张,复张后FiO2调整回40%。

干预措施代码:

Intervention:

After anesthetic induction and full onset of drug effects, endotracheal intubation was performed with the fraction of inspired oxygen (FiO2) set at 40%. Following the initiation of surgery, FiO2 was adjusted to the assigned inspired oxygen concentration for each group. Five minutes later, FiO2 was reduced to 21% for lung recruitment maneuver, and then restored to 40% upon the completion of lung recruitment.

Intervention code:

组别:

B组

样本量:

14

Group:

Group B

Sample size:

干预措施:

麻醉诱导后,待药物完全起效后行气管插管 FiO2设置为 40%,手术开始后 5min 后行肺复张。

干预措施代码:

Intervention:

After anesthetic induction and full onset of drug effects, endotracheal intubation was performed with the fraction of inspired oxygen (FiO2) set at 40%. Lung recruitment maneuver was conducted five minutes after the initiation of surgery.

Intervention code:

组别:

C组

样本量:

14

Group:

Group C

Sample size:

干预措施:

麻醉诱导后,待药物完全起效后行气管插管 FiO?设置为 40%,手术开始后调整 FiO?为 60%,5min 后行肺复张,复张后 FiO2调整回 40%。

干预措施代码:

Intervention:

After anesthetic induction and full onset of drug effects, endotracheal intubation was performed with the fraction of inspired oxygen (FiO2) set at 40%. Following the initiation of surgery, FiO2 was adjusted to 60%. Five minutes later, lung recruitment maneuver was conducted, and FiO2 was restored to 40% upon the completion of the maneuver.

Intervention code:

组别:

D组

样本量:

14

Group:

Group D

Sample size:

干预措施:

麻醉诱导后,待药物完全起效后行气管插管FiO2设置为40%,手术开始后调整FiO2为80%,5min后行肺复张,复张后FiO2调整回40%。

干预措施代码:

Intervention:

After anesthetic induction and full onset of drug effects, endotracheal intubation was performed with the fraction of inspired oxygen (FiO2) set at 40%. Following the initiation of surgery, FiO2 was adjusted to 80%. Five minutes later, lung recruitment maneuver was conducted, and FiO? was restored to 40% upon the completion of the maneuver.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

扬州 

Country:

China

Province:

Jiangsu

City:

Yangzhou

单位(医院):

江苏省苏北人民医院 

单位级别:

三甲 

Institution
hospital:

Subei People's Hospital of Jiangsu

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

肺顺应性回复时间

指标类型:

主要指标

Outcome:

Lung compliance response time

Type:

Primary indicator

测量时间点:

肺复张前后动态记录

测量方法:

根据麻醉机呼吸力学参数和公式Cdyn=Vt/(Pplat-PEEP)计算得出。

Measure time point of outcome:

Dynamic recording before and after recruitment manoeuvre

Measure method:

According to the respiratory mechanical parameters of the anesthesia machine, it was calculated according to the formula Cdyn=Vt/(Pplat-PEEP).

指标中文名:

低氧血症

指标类型:

次要指标

Outcome:

Hypoxemia

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

氧合指数

指标类型:

次要指标

Outcome:

Oxygenation index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肺不张

指标类型:

次要指标

Outcome:

Atelectasis

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肺部并发症

指标类型:

次要指标

Outcome:

Pulmonary complications

Type:

Secondary indicator

测量时间点:

术后3d内

测量方法:

改良肺部超声评分、术后3d内胸部影像学结果。

Measure time point of outcome:

Within 3 days after surgery

Measure method:

Modified lung ultrasound score and 3D intraoperative chest imaging results.

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用随机数字表法,使用 R 软件(版本 3.5.1,R Foundation for Statistics Computing,维也纳,奥地利)通过计算机生成随机分组,将患者分为 A 组、B 组、C 组、D 组。

Randomization Procedure (please state who generates the random number sequence and by what method):

A random number table method was adopted. Computer-generated randomization was performed using R software (Version 3.5.1, R Foundation for Statistics Computing, Vienna, Austria) to divide patients into four groups: Group A, Group B, Group C, and Group D.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

设盲水平为对受试者和数据收集者实施盲法;超声检查医生(BRK 或 HB)完全不知晓组分配情况。

Blinding:

Single-blind (hidden grouping of subjects) The blinding level was set as blinding of participants and data collectors; ultrasound examiners (BRK or HB) were completely unaware of the group assignments.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2026年3月后发送邮件至zhangyang901229@foxmail.com。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Send an email after March 2026 to zhangyang901229@foxmail.com .

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-02-26 16:09:35